With a better upfront offer on the table, enough bluebird bio investors have tendered their shares for the company's sale to ...

Shares of bluebird bio, Inc. (NASDAQ:BLUE) soared 50% in pre-market trading on Wednesday after the biotech firm revealed a ...

Investment firms The Carlyle Group Inc. (NASDAQ:CG) and SK Capital Partners, together with Beacon Parent Holdings, L.P., have ...

bluebird bio faces imminent bankruptcy unless a deal closes; current offer is $5 cash or $3 plus a low-value CVR. A rival ...

bluebird will focus on expanding manufacturing capacity and improving the treatment experience for patients and providers bluebird bio (NASDAQ: BLUE) (“bluebird”), a pioneer in gene therapies ...

SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (Nasdaq: BLUE) today announced that it has completed the restatement of its consolidated financial statements for the year ended December 31 ...

bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire ...

Bluebird bio will be acquired by investment firms Carlyle and SK Capital Partners, marking the end to its turbulent time as a ...

Joshua Cohen is a Boston-based writer who covers health policy. Bluebird bio is a highly innovative biotechnology company which develops gene therapies for several rare genetic disorders and cancers.

Bluebird Bio, Inc. (NASDAQ:BLUE) shares are trading higher on Wednesday following the news that Bluebird Bio, Carlyle, and SK Capital Partners, LP, have amended their definitive agreement.

Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million. Bluebird said late Friday that Ayrmid made ...

March 28 (Reuters) - Gene therapy maker bluebird bio (BLUE.O), opens new tab said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8 ...